DNMT1 and acute myeloid leukemia: Two inhibitors of DNMT, 5-azacytidine and 5-aza-2′-deoxycytidine, have been clinically approved by FDA for treatment of myelodysplastic syndrome, and the latter has been approved for acute myeloid leukemia (AML).